High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing
Authors:
Open Access
- 22 December 2022
- journal article
- research article
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (1)
Abstract
Background: Cystic fibrosis (CF) is a rare hereditary disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Recent therapies enable effective restoration of CFTR function of the most common F508delCFTRmutation. This shifts the unmet clinical need towards people with rareCFTRmutations such as nonsense mutations, of which G542X and W1282X are most prevalent. CFTR function measurements in patient-derived cell-based assays played a critical role in preclinical drug development for CF and may play an important role to identify new drugs for people with rareCFTRmutations.Methods: Here, we miniaturised the previously described forskolin-induced swelling (FIS) assay in intestinal organoids from a 96-well to a 384-well plate screening format. Using this novel assay, we tested CFTR increasing potential of a 1400-compound Food and Drug Administration (FDA)-approved drug library in organoids from donors with W1282X/W1282XCFTRnonsense mutations.Results: The 384-well FIS assay demonstrated uniformity and robustness based on coefficient of variation and Z’-factor calculations. In the primary screen, CFTR induction was limited overall, yet interestingly, the top five compound combinations that increased CFTR function all contained at least one statin. In the secondary screen, we indeed verified that four out of the five statins (mevastatin, lovastatin, simvastatin and fluvastatin) increased CFTR function when combined with CFTR modulators. Statin-induced CFTR rescue was concentration-dependent and W1282X-specific.Conclusions: Future studies should focus on elucidating genotype specificity and mode-of-action of statins in more detail. This study exemplifies proof of principle of large-scale compound screening in a functional assay using patient-derived organoids.Keywords
All Related Versions
Funding Information
- ZonMw (91214103)
This publication has 37 references indexed in Scilit:
- Cystic fibrosis: An inherited disease affecting mucin-producing organsThe International Journal of Biochemistry & Cell Biology, 2014
- Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator geneNature Genetics, 2013
- A functional CFTR assay using primary cystic fibrosis intestinal organoidsNature Medicine, 2013
- Identification of Synergistic Combinations of F508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) ModulatorsASSAY and Drug Development Technologies, 2010
- Development of Novel Aminoglycoside (NB54) with Reduced Toxicity and Enhanced Suppression of Disease-Causing Premature Stop MutationsJournal of Medicinal Chemistry, 2009
- PTC124 targets genetic disorders caused by nonsense mutationsNature, 2007
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004
- Use of Coefficient of Variation in Assessing Variability of Quantitative AssaysClinical and Vaccine Immunology, 2002
- A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening AssaysSLAS Discovery, 1999
- Mechanism of Action and Biological Profile of HMG CoA Reductase InhibitorsDrugs, 1988